International Isotopes shuffles management team
Following the retirement of chairman and treasurer Ira Lon Morgan, radiopharmaceutical manufacturer International Isotopes has made some additional changes to its senior management team (SCAN 12/15/99). The Denton, TX-based company, which is in
Following the retirement of chairman and treasurer Ira Lon Morgan, radiopharmaceutical manufacturer International Isotopes has made some additional changes to its senior management team (SCAN 12/15/99). The Denton, TX-based company, which is in the process of transitioning to fully commercial operations, announced that newly appointed CEO David Camp has taken on the additional responsibilities of president. Camp replaces former president Carl Seidel, who has left the company.
In addition, Bryce Drake has joined International Isotopes as director of support services. Drake takes over the position from George Butterworth, who has stepped into the new position of director of radioisotope production. Also new to the management team is Scott Colpitts, who has replaced Gaylord King as director of radiopharmaceutical manufacturing. King will continue to work closely with the firm.
In other company news, the Bureau of Radiation Control of the Texas Department of Health approved amendments to International Isotopes operational and development licenses that will allow the company to produce commercial quantities of radioisotopes for use in nuclear medicine procedures.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
New MRI Study Questions Use of Corticosteroid Injections for Knee OA
May 27th 2025Two years after intraarticular knee injections for knee osteoarthritis (OA), study participants who had corticosteroid knee injections had greater OA progression than control patients while the use of hyaluronic acid injections was associated with less OA progression.
